In IPMN, the positive prevalence of GNAS mutations in circulating cfDNA was found significantly high (70%), even more in IPMN with intestinal subtypes, whereas KRAS mutations were nearly absent. This evidence concerns the gene GNAS and pancreatic intraductal papillary-mucinous neoplasm.